Search for your doctor or find doctors accepting new patients.
Find out about our hospital visiting hours and policies.
Log In to MyUCSDChart to access your medical information
Find out about our academic nursing program.
ABS 4986g: Phase II randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of rhuMAb Beta7 in patients with moderate to severe ulcerative colitis (UC).
IM 129-005: Phase IIb randomized, placebo-controlled study to evaluate the clinical efficacy and safety of induction and maintenance therapy with BMS-936557 in patients with active ulcerative colitis (UC).
To learn more about these studies or to see whether you qualify, please contact firstname.lastname@example.org or call 858-657-5279.
GA 28084: Observational multicenter study in patients with Crohn’s disease for characterization of magnetic resonance enterography assays for assessment of disease activity protocol.
GSK 151: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of GSK1605786A in the treatment of subjects with moderately-to-severely active Crohn’s disease (CD).
OPERA: A double-blind, randomized, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of PF-00547659 in subjects with Crohn’s disease who are anti-TNF inadequate responders.
C87075 (SECURE): A non-interventional long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia) for Crohn’s Disease.
CNTO1275CRD3002: Phase 3, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the safety and efficacy of Ustekinumab induction therapy in subjects with moderately to severely active Crohn’s disease.
CNTO1275CRD3001: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy.
PREVENT: Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
*UC San Diego researchers have led other clinical trials in the approval of Remicade for the treatment of Crohn’s disease.
Official Web Site of the University of California, San Diego.